Stock Taper 
HELP
$12.22
▲ UP 3.82% (0.45)
KEY STATISTICS
Market Cap$758.06 M
52w High$14.35
52w Low$3.76
Dividend Yield—
Frequency—
P/E-2.93
Volume1.02M
Shares Out.61.98M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Michael I. Halstead
ABOUT
SECTOR
Healthcare
WENT PUBLIC
September 13, 2019
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
100
PRICE TARGET
Target High$16.00
Target Low$15.00
Target Median$15.50
Target Consensus$15.50
UPCOMING EARNINGS
DateNov 12, 2026
DayThursday
Rev. Est.—
NOV
12
THU
PRICE
$12.22 ▲ UP 3.82% (+$0.45)About Cybin Inc. Common Stock
https://www.helus.com ↗Clinical-stage biopharmaceutical company developing psychedelic-based therapeutics including CYB003 (deuterated psilocybin analog) for major depressive disorder and CYB004 (deuterated DMT) for generalized anxiety disorder
INDUSTRY
Medical - Pharmaceuticals
A PRODUCT CYBIN INC. COMMON STOCK IS KNOWN FOR
CYB003
A proprietary deuterated psilocybin analog in late-stage clinical trials for Major Depressive Disorder, with FDA Breakthrough Therapy Designation, highlighting its potential as a significant treatment advancement.
RATINGS SNAPSHOT
Overall rating: C
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book4
Overall Score2
MOST RECENT ANALYST GRADES
GRADE SUMMARY
BUY 4
4 GRADES IN THE LAST 12 MONTHS
